Apply for Nubeqa (darolutamide) Copay Card & Copay Assistance | QuickRx

Yes, completely free. QuickRx Specialty Pharmacy provides free enrollment and support for all Nubeqa (darolutamide) copay assistance programs including manufacturer copay cards and patient assistance programs. We never charge service fees for helping patients access medication savings.

What’s included at no cost:

• Application assistance for Nubeqa manufacturer copay cards
• Insurance verification and benefit checks
• Prior authorization support when needed
• Foundation grant applications for prostate cancer treatment
• Ongoing monitoring to ensure continuous savings
• Prescription coordination and specialty medication delivery

Nubeqa savings programs available:

For patients with commercial insurance, manufacturer copay cards for Nubeqa can significantly reduce your out-of-pocket costs.

For Medicare and Medicaid patients, foundation-based assistance programs provide grants that help cover medication expenses. These programs are also free to apply for with QuickRx’s help.

For uninsured patients, manufacturer patient assistance programs may provide Nubeqa at no cost or significantly reduced prices based on financial need.

Our team’s only goal is to make Nubeqa more affordable so you can focus on managing your prostate cancer without financial stress. Contact QuickRx at (917) 830-2525 or (800) 496-6111 to get started today.

Eligibility for Nubeqa copay assistance depends on your insurance type and your financial situation. QuickRx helps determine which programs you qualify for at no cost.

Eligibility criteria for Nubeqa copay cards:

Commercial insurance patients with coverage for Nubeqa typically qualify for manufacturer copay cards. Requirements usually include:

• Active commercial (private) health insurance that covers Nubeqa
• Valid prescription for darolutamide
• Treatment for FDA-approved indications (nmCRPC or mCSPC)
• US residency

Alternative assistance for other insurance types:

Medicare and Medicaid patients cannot use manufacturer copay cards due to federal regulations, but may qualify for foundation grants and other patient assistance programs specifically designed for government insurance beneficiaries.

Uninsured patients may qualify for manufacturer patient assistance programs that provide free or low-cost Nubeqa based on household income and financial need.

How QuickRx determines your eligibility:

When you contact QuickRx, we review your insurance coverage, prescription details, and financial situation to identify every Nubeqa assistance program you qualify for. We then handle all applications and enrollment paperwork on your behalf.

Call (917) 830-2525 or (800) 496-6111 to speak with a copay assistance specialist who can verify your eligibility for Nubeqa savings programs today.

Savings vary by insurance type and the assistance programs you qualify for. QuickRx works to maximize your savings through all available programs.

Potential Nubeqa copay assistance savings:

With commercial insurance, manufacturer copay cards can significantly reduce out-of-pocket costs for Nubeqa. The amount of savings depends on your insurance plan’s copay or coinsurance amount and the specific program benefit limits.

With Medicare or Medicaid, foundation grants and patient assistance programs help cover medication costs that Medicare doesn’t pay. Grant amounts vary by foundation and availability of funds.

For uninsured patients, manufacturer patient assistance programs may provide Nubeqa at no cost if you meet income eligibility requirements.

Why savings amounts vary:

• Your insurance plan’s coverage and cost-sharing structure
• Whether your medication requires specialty pharmacy dispensing
• Annual benefit caps on copay assistance programs
• Foundation funding availability at the time of application
• Your household income (for patient assistance programs)

QuickRx maximizes your savings:

Our specialty in oncology medications means we know how to layer multiple assistance programs to achieve maximum savings on your Nubeqa prescriptions. We monitor your benefits throughout the year and handle renewals to ensure uninterrupted assistance.

Yes, Medicare patients can access Nubeqa financial assistance, but not through manufacturer copay cards. Medicare beneficiaries may qualify for foundation grants and other patient assistance programs specifically designed to help cover out-of-pocket costs for prostate cancer medications.

Why Medicare patients can’t use copay cards:

Federal anti-kickback laws prohibit pharmaceutical manufacturers from offering copay cards to Medicare and Medicaid beneficiaries. This applies to Nubeqa.

Alternative assistance for Medicare patients:

QuickRx connects Medicare patients with alternative Nubeqa assistance programs including:

• Independent charitable foundations that provide grants for prostate cancer medications
• Disease-specific foundations focused on prostate cancer treatment
• Manufacturer patient assistance programs for qualifying patients
• State pharmaceutical assistance programs (SPAPs) where available

How QuickRx helps Medicare patients:

Our team specializes in navigating Medicare Part D coverage for specialty medications like Nubeqa. We help you understand your coverage, apply for foundation grants, navigate the coverage gap, and complete patient assistance program applications if you qualify.

Don’t let Medicare restrictions prevent you from affording your Nubeqa medication. Call QuickRx at (917) 830-2525 or (800) 496-6111 to explore all available assistance options.

If you’re struggling to afford Nubeqa, QuickRx Specialty Pharmacy can help you access financial assistance programs regardless of your insurance situation. We specialize in finding solutions for patients who cannot afford their prostate cancer medications.

Financial assistance options by insurance type:

With commercial insurance:

• Manufacturer copay cards for Nubeqa
• Disease-specific foundation grants for prostate cancer
• Premium assistance programs to help with insurance costs

With Medicare or Medicaid:

• Independent charitable foundation grants
• State pharmaceutical assistance programs
• Manufacturer patient assistance programs (if eligible)
• Medicare Extra Help/Low-Income Subsidy programs

Without insurance:

• Manufacturer patient assistance programs providing free medication
• Foundation grants for uninsured patients
• Hospital charity care programs
• Assistance finding affordable insurance coverage

Emergency medication access:

If you need your Nubeqa medication urgently and cannot afford it, contact QuickRx immediately. We can often expedite applications for emergency assistance programs to ensure you don’t miss doses of your critical medication.

Contact QuickRx urgently at (917) 830-2525 or (800) 496-6111 if you cannot afford your Nubeqa medication. We can help right away.

Nubeqa (darolutamide) is a prescription androgen receptor inhibitor approved by the FDA on July 30, 2019, for treating specific types of prostate cancer in adults. It works by competitively inhibiting androgen binding, androgen receptor nuclear translocation, and androgen receptor-mediated transcription. This results in decreased proliferation of prostate tumor cells and increased apoptosis, leading to decreased tumor volume.

FDA-approved indications for Nubeqa:

Metastatic castration-sensitive prostate cancer (mCSPC):

• Treatment as a single agent, or
• Treatment in combination with docetaxel chemotherapy

Non-metastatic castration-resistant prostate cancer (nmCRPC):

• Treatment as a single agent for patients at high risk of developing metastatic disease

How Nubeqa works:

Prostate cancer cells need testosterone to grow. Nubeqa blocks testosterone from attaching to androgen receptors in prostate cancer cells. The active metabolite ketodarolutamide has similar activity to darolutamide. By blocking this process, Nubeqa prevents testosterone from stimulating cancer cell growth, reduces prostate cancer cell proliferation, increases cancer cell death (apoptosis), and decreases tumor volume.

Clinical trial results:

• ARAMIS trial (nmCRPC): Extended metastasis-free survival to 40.4 months vs 18.4 months with placebo
• ARASENS trial (mCSPC with docetaxel): Improved overall survival with median OS not reached in the Nubeqa group vs 48.9 months with placebo
• ARANOTE trial (mCSPC without chemotherapy): Improved radiographic progression-free survival

Important note: Nubeqa is available only as a brand-name medication. There is currently no generic equivalent available in the United States.

Nubeqa is taken orally as tablets. Understanding proper administration is important for treatment effectiveness.

Standard dosing:

The recommended dose is 600 mg twice daily, which consists of:

• Two 300 mg tablets taken at each dose
• Taken twice daily (morning and evening)
• Must be administered with food
• Tablets should be swallowed whole

Why Nubeqa must be taken with food:

Bioavailability of darolutamide increases by 2- to 2.5-fold when administered with food compared to fasting conditions. Taking Nubeqa with food ensures you get the full therapeutic benefit of the medication.

Duration of treatment:

Treatment continues until disease progression or unacceptable toxicity occurs. Your oncologist will monitor your response to treatment and determine when to continue or stop therapy.

For patients receiving combination therapy:

If you’re taking Nubeqa in combination with docetaxel chemotherapy for mCSPC, the first dose of docetaxel should be administered within 6 weeks after starting Nubeqa. Patients typically receive up to 6 cycles of docetaxel, and Nubeqa continues throughout and after docetaxel treatment.

If you miss a dose:

Take it as soon as possible before the next scheduled dose. Do not take two doses at the same time to make up for a missed dose. Continue with your regular schedule.

Dose adjustments:

• Kidney function: Patients with severe kidney impairment (eGFR 15-29 mL/minute) not on dialysis take 300 mg twice daily
• Liver function: Patients with moderate liver impairment (Child-Pugh B) take 300 mg twice daily
• Side effects: Dose may be reduced to manage adverse reactions

Like all medications, Nubeqa can cause side effects. Many patients tolerate Nubeqa well, but it’s important to know what to watch for and when to contact your doctor.

Common side effects (occurring in more than 10% of patients):

• Fatigue or feeling weak (16%, including asthenia)
• Urinary tract infection (12%)
• Decreased neutrophils (16-20%)
• Elevated liver enzymes: increased ALT (28%), increased AST (23-32%), increased bilirubin (16-17%)

Side effects occurring in 1% to 10% of patients:

• Pain in arms or legs (6%)
• Skin rash (4%)
• Pneumonia (4%)
• Cardiac arrhythmia (9%)
• Heart failure (2%)
• Ischemic heart disease (3-4%)

Less common side effects (less than 1%):

• Acute myocardial infarction (heart attack)
• Seizure

Additional side effects (frequency not defined):

• Hypertension (high blood pressure)
• Diarrhea, nausea
• Hematuria (blood in urine), urinary retention
• Hemorrhage
• Spinal cord compression
• Musculoskeletal pain

When taking Nubeqa with docetaxel:

Additional side effects may include constipation, decreased appetite, and weight gain.

Important note: Nubeqa has a minimal to low emetic (nausea-causing) potential of less than 30%. Always report any new or worsening symptoms to your healthcare provider promptly.

While Nubeqa is generally well-tolerated, there are serious side effects and warnings patients should be aware of. The prescribing information includes specific warnings that require monitoring and potential dose modifications.

Ischemic Heart Disease Warning:

Ischemic heart disease, including grades 3 and 4 events, has occurred with Nubeqa. Some cases have been fatal. Androgen-deprivation therapy may increase cardiovascular disease risk. Before starting Nubeqa, healthcare providers should optimize management of cardiovascular risk factors. Patients should be monitored for signs and symptoms of ischemic heart disease. For grade 3 or 4 cardiovascular toxicity (ischemic heart disease): Nubeqa should be discontinued.

Seizure Warning:

Seizures have occurred in patients receiving Nubeqa, including grades 1 to 3 events. In clinical studies, seizure occurred from 38 to 1,754 days after starting treatment. It is not known if antiseizure medications can prevent darolutamide-related seizures. Patients should be advised of the seizure risk and avoid activities where sudden loss of consciousness could cause serious harm. If a seizure occurs: Healthcare providers should consider discontinuing Nubeqa.

Embryo-Fetal Toxicity Warning:

Based on its mechanism of action, Nubeqa can cause fetal harm and pregnancy loss. Male patients with female partners who could become pregnant should use effective contraception during treatment and for 1 week after the last dose.

Contact your doctor immediately if you experience:

• Chest pain or pressure
• Shortness of breath
• Seizures or convulsions
• Signs of infection (fever, chills, sore throat)
• Dark urine or yellowing of skin/eyes (jaundice)
• Unexplained bruising or bleeding
• Signs of allergic reaction (rash, hives, swelling, difficulty breathing)

Prostate cancer develops when cells in the prostate gland begin growing uncontrollably. Understanding prostate cancer helps patients better understand why medications like Nubeqa are important in treatment.

About the prostate:

The prostate is a walnut-sized gland located below the bladder in men that produces seminal fluid. Prostate cancer is one of the most common cancers in men.

Types of prostate cancer that Nubeqa treats:

Non-metastatic castration-resistant prostate cancer (nmCRPC): Cancer that continues growing despite low testosterone levels (castration-resistant), has not spread to other body parts (non-metastatic), and patients are at high risk of the cancer spreading.

Metastatic castration-sensitive prostate cancer (mCSPC): Cancer that has spread to other parts of the body (metastatic) but still responds to hormone therapy (castration-sensitive).

Treatment approaches for prostate cancer:

• Active surveillance for slow-growing cancers
• Surgery to remove the prostate (prostatectomy)
• Radiation therapy
• Hormone therapy (androgen deprivation therapy or ADT)
• Chemotherapy
• Targeted therapies like Nubeqa (darolutamide)
• Immunotherapy

How Nubeqa fits into treatment:

Nubeqa belongs to a class of medications called androgen receptor inhibitors. It blocks testosterone from stimulating cancer cell growth when added to standard hormone therapy (ADT). Clinical trials have shown that adding Nubeqa to ADT significantly extends survival and delays disease progression.

Yes, Nubeqa can interact with various medications due to its effects on drug-metabolizing enzymes and transporters. It’s important to tell your doctor about all medications you take.

How Nubeqa affects drug metabolism:

• Substrate of: CYP3A4 (minor), P-glycoprotein (minor), UGT1A1, UGT1A9
• Inhibits: BCRP, OATP1B1/1B3 transporters
• Induces: CYP3A4 (weak)

Important drug interactions:

Strong CYP3A4 inhibitors: Combined P-gp and strong CYP3A4 inhibitors can increase Nubeqa exposure, may increase risk of adverse reactions, and patients should be monitored more frequently.

Strong CYP3A4 inducers: Combined P-gp and strong CYP3A4 inducers may decrease Nubeqa levels, could reduce effectiveness, and should be avoided.

BCRP substrates: Nubeqa can increase exposure to BCRP substrates and may increase risk of toxicities. Concomitant use should be avoided where possible.

OATP1B1/1B3 substrates: Nubeqa can increase concentrations of these substrates. Rosuvastatin dose should be limited to 5 mg daily when combined with Nubeqa.

Hormonal contraceptives: Effectiveness may be decreased. Additional contraceptive methods may be needed.

Tell your healthcare providers about:

• All prescription medications
• Over-the-counter drugs
• Vitamins and supplements
• Herbal products

Regular monitoring is essential during Nubeqa treatment to ensure the medication is working effectively and to detect any potential side effects early.

Recommended monitoring includes:

Liver and kidney function: Monitor hepatic (liver) and kidney function tests as clinically necessary.

Cardiovascular monitoring:

• Assess for cardiovascular risk factors (diabetes, dyslipidemia, hypertension)
• Monitor for signs and symptoms of ischemic heart disease
• Baseline and serial ECGs recommended for patients at risk of QTc prolongation
• Estimate 10-year cardiovascular disease risk before treatment
• Assess cardiovascular risk annually during treatment

Comprehensive assessment before starting treatment:

• Complete history and physical examination
• Screening for cardiovascular disease risk factors
• Assessment for hypertension, diabetes, dyslipidemia, obesity, and smoking

Seizure monitoring: Monitor for seizure activity. Patients should report any seizure symptoms immediately.

Cancer monitoring:

• PSA (prostate-specific antigen) levels periodically
• Imaging studies to assess cancer response
• Regular oncology appointments

Report to your doctor immediately:

• Chest pain or shortness of breath
• Seizure activity
• Signs of infection
• Unusual bleeding or bruising
• Changes in urination patterns

Nubeqa has demonstrated significant effectiveness in clinical trials for both of its approved indications. The medication has shown the ability to substantially extend the time before cancer progresses and improve overall survival.

ARAMIS trial (for nmCRPC):

• Patients taking Nubeqa had median metastasis-free survival of 40.4 months
• Patients taking placebo had median metastasis-free survival of 18.4 months
• Nubeqa more than doubled the time before cancer spread
• Also showed improvements in time to pain progression and time to first symptomatic skeletal event

ARASENS trial (for mCSPC with docetaxel):

• Patients receiving Nubeqa plus docetaxel had significantly improved overall survival
• Median overall survival not reached in the Nubeqa group
• Median overall survival was 48.9 months in the placebo group

ARANOTE trial (for mCSPC without chemotherapy):

• Demonstrated improved radiographic progression-free survival
• Led to FDA approval for Nubeqa as single agent for mCSPC

These clinical results have established Nubeqa as an important treatment option for appropriate patients with advanced prostate cancer. Your oncologist can discuss how Nubeqa’s benefits and risks apply to your specific situation.

Many patients with other health conditions can safely take Nubeqa, though some conditions may require dose adjustments or additional monitoring. Discuss your complete medical history with your oncologist before starting treatment.

Kidney function considerations:

• Mild to moderate impairment (eGFR 30-89 mL/minute): No dose adjustment needed
• Severe impairment (eGFR 15-29 mL/minute) not on dialysis: Reduced dose of 300 mg twice daily (due to ~2.5-fold increased drug exposure)
• End-stage kidney disease (eGFR below 15 mL/minute): Has not been studied

Liver function considerations:

• Mild impairment (Child-Pugh Class A): No dose adjustment needed
• Moderate impairment (Child-Pugh Class B): Reduced dose of 300 mg twice daily (due to ~1.9-fold increased drug exposure)
• Severe impairment (Child-Pugh Class C): Has not been studied

Heart conditions:

Patients with existing cardiovascular disease or risk factors require careful consideration and additional monitoring due to the warning for ischemic heart disease. Healthcare team should optimize management of cardiovascular risk factors before and during treatment.

Seizure history:

Patients with a history of seizures or conditions that may predispose to seizures should discuss risks with their healthcare provider, as seizures have been reported with Nubeqa treatment.

Age considerations:

In clinical trials, 88% of patients were 65 years or older and 49% were 75 years or older. No clinically meaningful differences in safety or efficacy compared to younger patients. Standard adult dosing applies to older adults.

Proper storage of Nubeqa is important to maintain the medication’s effectiveness throughout your treatment.

Storage temperature:

• Store at room temperature: 20°C to 25°C (68°F to 77°F)
• Temperature excursions permitted: 15°C to 30°C (59°F to 86°F)
• Brief exposure to temperatures slightly outside the ideal range during normal handling is acceptable

Storage conditions:

• Keep the bottle tightly closed after initial opening
• Store in the original container
• Protect from moisture
• Do not transfer to a different container for extended periods

Hazardous drug handling:

Nubeqa is classified as a medication that may meet criteria for a hazardous drug due to its mechanism of action. Use appropriate precautions for receiving, handling, storage, and disposal. Follow NIOSH and USP 800 recommendations.

General medication safety:

• Keep Nubeqa and all medications out of reach of children and pets
• Do not use tablets that appear damaged or discolored
• Do not use if the expiration date has passed
• Dispose of unused medication properly

QuickRx Specialty Pharmacy is a nationwide specialty pharmacy licensed in all 50 states with specific expertise in oncology medications like Nubeqa. Our dedicated team provides comprehensive support to ensure you can access and afford your medication throughout your treatment.

Copay assistance expertise:

• Current knowledge of all available Nubeqa assistance programs
• Understanding of eligibility requirements and application processes
• Dedicated patient navigators handle all paperwork
• We’ve helped thousands of patients access significant savings
• Free copay assistance services – we never charge fees

Clinical pharmacy services:

• Pharmacists review medications for potential interactions
• Counseling on proper administration and side effect management
• Coordination with your oncology team
• 24/7 pharmacist availability for questions

Convenient services:

• Home delivery of your medication
• Refill reminders
• Ongoing support throughout your treatment
• Prior authorization assistance

Insurance support:

• We accept most insurance plans
• Work directly with your insurance company
• Handle prior authorizations
• Navigate coverage issues on your behalf

Contact us today at (917) 830-2525 or (800) 496-6111 to experience the QuickRx difference.